However, the introduction of sodium–glucose cotransporter 2 (SGLT-2) inhibitors has transformed the landscape of T2DM and CVD treatment, offering cardiovascular benefits that extend beyond glycemic control [7,8]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.